[{"id":"33cf62f6-c277-47f8-8250-b82304b5aabf","acronym":"NBO-ONCO","url":"https://clinicaltrials.gov/study/NCT06946004","created_at":"2025-09-07T01:24:29.306Z","updated_at":"2025-09-07T01:24:29.306Z","phase":"","brief_title":"Normobaric Oxygen Therapy in Colorectal Cancer Patients","source_id_and_acronym":"NCT06946004 - NBO-ONCO","lead_sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","biomarkers":" CCL3","pipe":"","alterations":" ","tags":["CCL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-04-27"},{"id":"7751beea-ed0b-4a4d-8397-acffe8af0a14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432378","created_at":"2021-01-18T11:38:27.441Z","updated_at":"2024-07-02T16:35:00.114Z","phase":"Phase 1/2","brief_title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","source_id_and_acronym":"NCT02432378","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX","pipe":"","alterations":" ","tags":["IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Suspended","enrollment":" Enrollment 25","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-30"},{"id":"e560ec4a-8063-4c7a-880e-a6ea19e8745c","acronym":"BHARAT-1","url":"https://clinicaltrials.gov/study/NCT05607199","created_at":"2024-02-01T04:20:23.252Z","updated_at":"2024-07-02T16:35:21.461Z","phase":"Phase 1","brief_title":"A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics","source_id_and_acronym":"NCT05607199 - BHARAT-1","lead_sponsor":"Aurigene Discovery Technologies Limited","biomarkers":" IL6 • TNFA • IL1A • CCL3","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1A • CCL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AUR-103"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/16/2022","start_date":" 09/16/2022","primary_txt":" Primary completion: 09/16/2025","primary_completion_date":" 09/16/2025","study_txt":" Completion: 10/16/2026","study_completion_date":" 10/16/2026","last_update_posted":"2024-01-31"},{"id":"1a5afad7-27ed-4e1a-9e4f-e5b3eebab5a7","acronym":"DERIVe","url":"https://clinicaltrials.gov/study/NCT03688178","created_at":"2021-01-18T18:04:45.994Z","updated_at":"2024-07-02T16:35:42.645Z","phase":"Phase 2","brief_title":"DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab","source_id_and_acronym":"NCT03688178 - DERIVe","lead_sponsor":"Annick Desjardins, MD","biomarkers":" MGMT • IL2RA • CD4 • FOXP3 • CCL3 • ISG20","pipe":"","alterations":" ","tags":["MGMT • IL2RA • CD4 • FOXP3 • CCL3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • varlilumab (CDX 1127)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 08/26/2020","start_date":" 08/26/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-07-19"},{"id":"398611ec-32d5-4767-9ab0-d167a02f0c96","acronym":"ICE","url":"https://clinicaltrials.gov/study/NCT05727813","created_at":"2023-02-14T18:02:36.078Z","updated_at":"2024-07-02T16:35:55.606Z","phase":"","brief_title":"To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)","source_id_and_acronym":"NCT05727813 - ICE","lead_sponsor":"University of Roma La Sapienza","biomarkers":" IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/16/2023","primary_completion_date":" 01/16/2023","study_txt":" Completion: 01/27/2023","study_completion_date":" 01/27/2023","last_update_posted":"2023-02-14"},{"id":"8845632f-aaf2-4910-998f-1dd54aea928e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00319748","created_at":"2021-01-18T01:06:04.323Z","updated_at":"2024-07-02T16:36:56.604Z","phase":"Phase 2","brief_title":"Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers","source_id_and_acronym":"NCT00319748","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HER-2 • ER • PGR • TNFA • CCL3 • CD40LG • IL1RN","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["HER-2 • ER • PGR • TNFA • CCL3 • CD40LG • IL1RN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 12/01/2007","primary_completion_date":" 12/01/2007","study_txt":" Completion: 12/01/2008","study_completion_date":" 12/01/2008","last_update_posted":"2019-08-26"},{"id":"549a1ef6-eba8-48b1-bfb4-4b61cafd2aa1","acronym":"REBUILD","url":"https://clinicaltrials.gov/study/NCT03475628","created_at":"2021-01-18T17:07:31.443Z","updated_at":"2024-07-02T16:37:12.839Z","phase":"Phase 2","brief_title":"Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03475628 - REBUILD","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" DKK1 • CCL3","pipe":"","alterations":" ","tags":["DKK1 • CCL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 57","initiation":"Initiation: 02/21/2018","start_date":" 02/21/2018","primary_txt":" Primary completion: 06/20/2019","primary_completion_date":" 06/20/2019","study_txt":" Completion: 02/20/2020","study_completion_date":" 02/20/2020","last_update_posted":"2018-03-23"},{"id":"c9c7fea3-7791-4080-9a22-7fbd5d0d8309","acronym":"","url":"https://clinicaltrials.gov/study/NCT02746432","created_at":"2021-01-18T13:27:20.104Z","updated_at":"2024-07-02T16:37:18.607Z","phase":"Phase 4","brief_title":"Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial","source_id_and_acronym":"NCT02746432","lead_sponsor":"King Saud University","biomarkers":" IFNG • IL6 • CXCL8 • CD4 • IL10 • IL18 • TGFB1 • CCL3 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • CXCL8 • CD4 • IL10 • IL18 • TGFB1 • CCL3 • IL1B"],"overall_status":"Unknown status","enrollment":" Enrollment 144","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2017-08-22"}]